APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology

Abstract Background Apolipoprotein E ε4 (APOE4) is the strongest genetic risk factor for late-onset Alzheimer’s disease (LOAD). A recent case report identified a rare variant in APOE, APOE3-R136S (Christchurch), proposed to confer resistance to autosomal dominant Alzheimer’s Disease (AD). However, i...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kristine M. Tran, Nellie E. Kwang, Claire A. Butler, Angela Gomez-Arboledas, Shimako Kawauchi, Cassandra Mar, Donna Chao, Rocio A. Barahona, Celia Da Cunha, Kate I. Tsourmas, Zechuan Shi, Shuling Wang, Sherilyn Collins, Amber Walker, Kai-Xuan Shi, Joshua A. Alcantara, Jonathan Neumann, Duc M. Duong, Nicholas T. Seyfried, Andrea J. Tenner, Frank M. LaFerla, Lindsay A. Hohsfield, Vivek Swarup, Grant R. MacGregor, Kim N. Green
Format:	Article
Language:	English
Published:	BMC 2025-01-01
Series:	Molecular Neurodegeneration
Subjects:	APOE Christchurch PS19 5xFAD Microglia DAM Amyloid
Online Access:	https://doi.org/10.1186/s13024-024-00793-x
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology

Similar Items